早期类风湿关节炎ESPOIR队列10年良好结局及预测因素
ESPOIR队列纳入813例早期RA患者(病程<6个月、未用过DMARD),随访10年发现521例(64.1%)可评估者中52.4%达DAS28缓解、14.1%达无药缓解,结构进展轻微,ACPA阳性为长期结局的稳健预测因素。
要点
- 10年时52.4%达DAS28缓解、14.1%无药缓解、39.7%达CDAI缓解。
- 结构进展轻微,改良Sharp评分平均变化11.0(17.9),仅6.5%需大关节手术。
- ACPA阳性被证实为长期结局的稳健预测因素。
核心结论
- 2000年代初诊断的早期RA患者10年结局非常轻微,明显优于1993年招募的既往队列。
- 当前良好结局可能与真实世界患者更密集的治疗相关。
研究设计与样本
- ESPOIR起始队列,2003至2005年纳入813例早期关节炎(<6个月)且高度可能为RA、从未使用DMARD的患者。
- 采用多因素分析评估结局预测因素。
主要发现
- 521例(64.1%)RA患者随访10年,35例(4.3%)死亡,与法国一般人群相似。
- 480例(92.1%)接受DMARD,174例(33.4%)至少接受一种生物DMARD,其中13.6%在2年内使用。
- 10年时273例(52.4%)达DAS28缓解,40.1%达持续缓解,14.1%达无药缓解,39.7%达CDAI缓解。
- 半数患者HAQ-DI<0.5,SF-36躯体成分和疼痛控制良好。
- 结构进展轻微,改良Sharp评分较基线平均变化11.0(17.9),仅34例(6.5%)需大关节手术;10年间相当数量患者出现新发合并症。
关键数值与推荐
- DAS28缓解52.4%,持续缓解40.1%,无药缓解14.1%,CDAI缓解39.7%。
- HAQ-DI<0.5者占半数,改良Sharp评分平均变化11.0(17.9),大关节手术率6.5%。
- ACPA阳性为长期结局的稳健预测因素。
临床怎么用
- 早期RA经密集DMARD治疗可获得良好10年结局,支持早期积极干预。
- ACPA阳性可用于识别长期结局较差的高危患者。
- 随访中需关注新发合并症。
局限性
- 原文摘要未报告失访原因及预测因素的具体效应值。
- 原文摘要未报告多因素分析的具体变量和校正因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome. METHODS: From 2003 to 2005, 813 patients were included if they had early arthritis (<6 months) with a high probability of RA and had never been prescribed DMARDs. Multivariate analysis was used to evaluate predictors of outcome. RESULTS: In total, 521 (64.1%) RA patients were followed up for 10 years; 35 (4.3%) died, which appears to be similar to the French general population. Overall, 480 (92.1%) patients received a DMARD; 174 (33.4%) received at least one biologic DMARD, 13.6% within 2 years. At year 10, 273 (52.4%) patients were in DAS28 remission, 40.1% in sustained remission, 14.1% in drug-free remission, 39.7% in CDAI remission. Half of the patients achieved a health assessment questionnaire-disability index (HAQ-DI) < 0.5. SF-36 physical component and pain were well controlled. Structural progression was weak, with a mean change from baseline in modified Sharp score of 11.0 (17.9). Only 34 (6.5%) patients required major joint surgery. A substantial number of patients showed new comorbidities over 10 years. Positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a robust predictor of long-term outcome. CONCLUSIONS: We report a very mild 10-year outcome of a large cohort of patients with early RA diagnosed in the early 2000s, which was much better than results for a previous cohort of patients who were recruited in 1993. This current favourable outcome may be related to more intensive care for real-life patients.
引用
- Combe B, Rincheval N, Berenbaum F, et al. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford). 2021. PMID: 33961011. doi:10.1093/rheumatology/keab398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。